Contact
searchSearch
HMP Global
Login

Oncology

Featured

News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
Bertrand Tombal, MD, PhD
Videos
Radium-223 Plus Enzalutamide Improves Survival in Bone-Predominant Metastatic Castration-Resistant Prostate Cancer
03/05/2026
Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.
Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.
Bertrand Tombal, MD, PhD,...
03/05/2026
Oncology
Ranee Mehra, MD
Videos
First-Line Amivantamab Plus Pembrolizumab in HPV-Negative Head and Neck Squamous Cell Carcinoma
03/05/2026
Ranee Mehra, MD discusses results from cohort 2 of the phase 1b/2 OrigAMI-4 study, which evaluated first-line subcutaneous amivantamab plus pembrolizumab in HPV-negative, PD-L1–positive head and neck squamous cell carcinoma.
Ranee Mehra, MD discusses results from cohort 2 of the phase 1b/2 OrigAMI-4 study, which evaluated first-line subcutaneous amivantamab plus pembrolizumab in HPV-negative, PD-L1–positive head and neck squamous cell carcinoma.
Ranee Mehra, MD discusses...
03/05/2026
Oncology
Varun Monga, MBBS
Videos
Cabozantinib Plus Temozolomide Shows Clinical Activity in Advanced Soft Tissue Sarcomas
03/05/2026
Varun Monga, MBBS, discusses results from a single-arm, phase 2 trial evaluating cabozantinib plus temozolomide in patients with unresectable or metastatic soft tissue sarcomas.
Varun Monga, MBBS, discusses results from a single-arm, phase 2 trial evaluating cabozantinib plus temozolomide in patients with unresectable or metastatic soft tissue sarcomas.
Varun Monga, MBBS, discusses...
03/05/2026
Oncology
Thomas Roberts, MD, MBA
Videos
Tumor-Informed ctDNA MRD Assay May Predict Recurrence and Survival Outcomes in HPV-Independent Head and Neck Cancer
03/05/2026
Thomas Roberts, MD, MBA, shared study results which analyzed a tumor-informed ctDNA-based MRD assay in primarily HPV-independent, locally advanced head and neck squamous cell carcinoma.
Thomas Roberts, MD, MBA, shared study results which analyzed a tumor-informed ctDNA-based MRD assay in primarily HPV-independent, locally advanced head and neck squamous cell carcinoma.
Thomas Roberts, MD, MBA, shared...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology
Quiz
Serum LDH and α-HBDH Levels in SCLC
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
News
Real-World Analysis Evaluates Survival and Quality of Life Patterns of Third-Line Systemic Therapies for ES-SCLC
03/04/2026
Emily Estrada
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was...
03/04/2026
Oncology
News
Sequential Thoracic Radiotherapy After Chemoimmunotherapy Associated With Improved Survival in ES-SCLC
03/04/2026
Emily Estrada
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with...
03/04/2026
Oncology
Quiz
Predictive Accuracy of Whole-Brain Radiotherapy Response in SCLC With Brain Metastases
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology

Videos

Bertrand Tombal, MD, PhD
Videos
Radium-223 Plus Enzalutamide Improves Survival in Bone-Predominant Metastatic Castration-Resistant Prostate Cancer
03/05/2026
Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.
Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.
Bertrand Tombal, MD, PhD,...
03/05/2026
Oncology
Ranee Mehra, MD
Videos
First-Line Amivantamab Plus Pembrolizumab in HPV-Negative Head and Neck Squamous Cell Carcinoma
03/05/2026
Ranee Mehra, MD discusses results from cohort 2 of the phase 1b/2 OrigAMI-4 study, which evaluated first-line subcutaneous amivantamab plus pembrolizumab in HPV-negative, PD-L1–positive head and neck squamous cell carcinoma.
Ranee Mehra, MD discusses results from cohort 2 of the phase 1b/2 OrigAMI-4 study, which evaluated first-line subcutaneous amivantamab plus pembrolizumab in HPV-negative, PD-L1–positive head and neck squamous cell carcinoma.
Ranee Mehra, MD discusses...
03/05/2026
Oncology
Varun Monga, MBBS
Videos
Cabozantinib Plus Temozolomide Shows Clinical Activity in Advanced Soft Tissue Sarcomas
03/05/2026
Varun Monga, MBBS, discusses results from a single-arm, phase 2 trial evaluating cabozantinib plus temozolomide in patients with unresectable or metastatic soft tissue sarcomas.
Varun Monga, MBBS, discusses results from a single-arm, phase 2 trial evaluating cabozantinib plus temozolomide in patients with unresectable or metastatic soft tissue sarcomas.
Varun Monga, MBBS, discusses...
03/05/2026
Oncology
Thomas Roberts, MD, MBA
Videos
Tumor-Informed ctDNA MRD Assay May Predict Recurrence and Survival Outcomes in HPV-Independent Head and Neck Cancer
03/05/2026
Thomas Roberts, MD, MBA, shared study results which analyzed a tumor-informed ctDNA-based MRD assay in primarily HPV-independent, locally advanced head and neck squamous cell carcinoma.
Thomas Roberts, MD, MBA, shared study results which analyzed a tumor-informed ctDNA-based MRD assay in primarily HPV-independent, locally advanced head and neck squamous cell carcinoma.
Thomas Roberts, MD, MBA, shared...
03/05/2026
Oncology
Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai
Videos
FX-909 Shows Biomarker-Driven Activity in Advanced Urothelial Cancer
03/02/2026
Matthew Galsky, MD
Matthew Galsky, MD, discusses results from a phase 1 study evaluating FX-909 in patients with advanced urothelial cancer.
Matthew Galsky, MD, discusses results from a phase 1 study evaluating FX-909 in patients with advanced urothelial cancer.
Matthew Galsky, MD, discusses...
03/02/2026
Oncology
Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai
Videos
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Muscle-Invasive Bladder Cancer
03/02/2026
Matthew Galsky, MD
Matthew Galsky, MD, discusses results from the phase 3 KEYNOTE-B15/EV-304 study evaluating perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer.
Matthew Galsky, MD, discusses results from the phase 3 KEYNOTE-B15/EV-304 study evaluating perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer.
Matthew Galsky, MD, discusses...
03/02/2026
Oncology
Ira Zackon, MD
Videos
Real-World Analysis Finds Venetoclax-Based Induction Effective for Very Elderly Patients With Acute Myeloid Leukemia
03/02/2026
Ira Zackon, MD
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results...
03/02/2026
Oncology
Richard Finn, MD
Videos
Regorafenib Demonstrates Consistent Benefit in Unresectable Hepatocellular Carcinoma
03/02/2026
Richard S. Finn
Richard Finn, MD, discusses post hoc analysis results from the REFINE study assessing regorafenib in patients with unresectable hepatocellular carcinoma.
Richard Finn, MD, discusses post hoc analysis results from the REFINE study assessing regorafenib in patients with unresectable hepatocellular carcinoma.
Richard Finn, MD, discusses post...
03/02/2026
Oncology
Pooja Ghatalia, MD
Videos
RETAIN-2 Supports Response-Adapted Bladder Preservation in Muscle-invasive Bladder Cancer
02/27/2026
Pooja Ghatalia, MD
Pooja Ghatalia, MD, discusses results from the phase 2 RETAIN-2 trial and integrated ctDNA analysis from RETAIN-1 and RETAIN-2 evaluating response-adapted bladder preservation in muscle-invasive bladder cancer.
Pooja Ghatalia, MD, discusses results from the phase 2 RETAIN-2 trial and integrated ctDNA analysis from RETAIN-1 and RETAIN-2 evaluating response-adapted bladder preservation in muscle-invasive bladder cancer.
Pooja Ghatalia, MD, discusses...
02/27/2026
Oncology
Tomotaka Suzuki, MD
Videos
Addition of Bortezomib to Daratumumab Maintenance Therapy Does Not Improve Progression-Free Survival in Transplant-Ineligible Multiple Myeloma: JCOG1911/ B-DASH Trial
02/27/2026
Tomotaka Suzuki, MD
According to results from a phase 3 trial, adding bortezomib to daratumumab maintenance did not improve PFS in transplant-ineligible patients with newly diagnosed multiple myeloma who responded to daratumumab, melphalan, prednisolone, and...
According to results from a phase 3 trial, adding bortezomib to daratumumab maintenance did not improve PFS in transplant-ineligible patients with newly diagnosed multiple myeloma who responded to daratumumab, melphalan, prednisolone, and...
According to results from a...
02/27/2026
Oncology

Insights From the ASCO Annual Meeting

Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Herbert Loong, MD
Conference Coverage
BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer
07/24/2025
Herbert Loong, MD
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology
News
Real-World Analysis Evaluates Survival and Quality of Life Patterns of Third-Line Systemic Therapies for ES-SCLC
03/04/2026
Emily Estrada
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was...
03/04/2026
Oncology
News
Sequential Thoracic Radiotherapy After Chemoimmunotherapy Associated With Improved Survival in ES-SCLC
03/04/2026
Emily Estrada
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with...
03/04/2026
Oncology
News
Real-World Analysis Identifies Clinical Predictors of Long-Term Response and Survival with Atezolizumab Plus Chemotherapy in ES-SCLC: CLINATEZO Study
03/03/2026
Emily Estrada
In a real-world ES-SCLC cohort treated with atezolizumab plus chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response.
In a real-world ES-SCLC cohort treated with atezolizumab plus chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response.
In a real-world ES-SCLC cohort...
03/03/2026
Oncology
News
Concurrent Radiotherapy With Tarlatamab Demonstrates Low Toxicity, Promising Disease Control in Extensive-Stage Small Cell Lung Cancer
03/03/2026
Emily Estrada
In patients with extensive-stage small cell lung cancer, concurrent radiotherapy during tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression.
In patients with extensive-stage small cell lung cancer, concurrent radiotherapy during tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression.
In patients with extensive-stage...
03/03/2026
Oncology
News
Auceliciclib Demonstrates Favorable Safety and Preliminary Activity in Advanced Solid Tumors and Recurrent High-Grade Glioma
03/03/2026
Emily Estrada
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated...
03/03/2026
Oncology
News
Dapolsertib Well-Tolerated, Demonstrates Clinical Activity in Acute Myeloid Leukemia
03/02/2026
Emily Estrada
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a...
03/02/2026
Oncology
FDA Approval
FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC
02/26/2026
Emily Estrada
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the...
02/26/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use